Clinical trials: Minimal Disease, Residual
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia
Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab
A study on the effectiveness and safety of haploidentical hematopoietic stem cell transplantation in patients with MRD positive CD19+ ALL treated with conditioning regimens containing Blinatumomab
- Trial name
- NCT06125106
- Testing
- Blinatumomab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang University
Multiple Myeloma, Minimal Residual Disease
Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry
Multiple myeloma (MM) is a severe plasma cell cancer caused by proliferation and accumulation of malignant plasma cells in the bone marrow. Novel therapies have improved responses and survival considerably.
- Trial name
- NCT07691034
- Testing
- Mass spectrometry
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Lymphocytic Leukemia
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
The purpose of this study is to assess the therapeutic efficacy of mosunetuzumab, a bispecific antibody targeting CD20 and CD3 in patients who have detectable chronic lymphocytic leukemia (CLL) after receiving Bruton's tyrosine…
- Trial name
- NCT07566364
- Testing
- Mosunetuzumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
The goal of this clinical trial is to learn whether the Ad5.F35-hGCC-PADRE vaccine is safe and can stimulate an immune response against gastrointestinal (GI) cancers in patients with pancreatic, colorectal, esophageal, gastric…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8
- Trial name
- NCT04111172
- Testing
- Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Thomas Jefferson University
Cutaneous Squamous Cell Carcinoma
ctDNA in Cutaneous Squamous Cell Carcinoma
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response…
- Trial name
- NCT06875609
- Testing
- Blood and Tissue Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Limited Stage Small Cell Lung Cancer
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy versus placebo in patients with LS-SCLC who had not progressed following Concurrent or Sequential Chemoradiotherapy.
- Trial name
- SURPASS (NCT05623267)
- Testing
- Sugemalimab
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
Elimination of Minimal Residual Disease After Transplant
This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the…
- Trial name
- EMAT (NCT05690984)
- Testing
- Dexamethasone, Isatuximab, Lenalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia (AML)
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
The purpose of this study is to find out if azacitidine and venetoclax are an effective treatment approach to get rid of or lower measurable residual disease (MRD) in people with acute myeloid leukemia (AML) who have received…
- Trial name
- NCT06773208
- Testing
- Azacitidine (AZC), Venetoclax
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B Acute Lymphoblastic Leukemia, CD19 Positive
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
This phase I trial studies the side effects of CD19/CD22 chimeric antigen receptor (CAR) T cells when given together with chemotherapy and NKTR-255, and to see how well they work in treating patients with CD19 positive B acute…
- Conditions
- B Acute Lymphoblastic Leukemia, CD19 Positive, Minimal Residual Disease, Philadelphia Chromosome Positive
- Trial name
- NCT03233854
- Testing
- Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Stanford University
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace
Acute Myeloid Leukemia (AML)
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Venetoclax (Ven) resistance is common in the treatment of acute myeloid leukemia (AML). Patients with Ven resistance have poor response and survival, except those with specific targeted therapy.
- Trial name
- HLA-AML (NCT07813390)
- Testing
- Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Guangdong Second Provincial General Hospital
Colorectal Cancer
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer.
- Trial name
- MRD (NCT05210283)
- Testing
- MRD
- Where
- 32 sites in United States, Canada
- Volunteers
- 1,017 people
- Sponsor
- Exact Sciences Corporation
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
- Trial name
- NCT07134088
- Testing
- Blinatumomab
- Where
- 5 sites in United States, Japan
- Volunteers
- 104 people
- Sponsor
- Amgen
CLL
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%).
- Trial name
- NCT04639362
- Testing
- ibrutinib, venetoclax, obinutuzumab, ibrutinib, venetoclax
- Where
- 27 sites in Denmark, Netherlands
- Volunteers
- 85 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
- Trial name
- NCT06536959
- Testing
- PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing 302 Hospital
Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD)
Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Detectable measurable residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) for overall survival (OS) and disease-free survival (DFS).
- Trial name
- NCT06886074
- Testing
- Short course of blinatumomab
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Leukemia, Myelodysplastic Syndromes
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
This is a Phase I, multicenter, open-label, non-randomized study of matched unrelated donor BPX-501 T cell infusion in adult subjects with hematological malignancies presenting with recurrent disease minimal residual disease…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Lymphomas, Multiple Myeloma
- Trial name
- NCT02786485
- Testing
- rivogenlecleucel, Rimiducid
- Sponsor
- Bellicum Pharmaceuticals
Colon Cancer, Resected Stage
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for…
- Trial name
- NCT05040568
- Testing
- Cetuximab, Expanded CB-NK cells, Fludarabine phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
This retrospective multicentre cohort evaluates the agreement of measurable residual disease (MRD) detection in acute myeloid leukaemia (AML) using two flow-cytometry gating approaches.
- Trial name
- DUALFLOW (NCT07269067)
- Testing
- Conventional gating, Automated gating
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux